June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
One-year results of intravitreal aflibercept injections for neovascular age-related macular degeneration using a treat and extend regimen
Author Affiliations & Notes
  • Mio Hosokawa
    ophthalmology, okayama university, Okayama city, Japan
  • Yuki Morizane
    ophthalmology, okayama university, Okayama city, Japan
  • Shuhei Kimura
    ophthalmology, okayama university, Okayama city, Japan
  • Yusuke Shiode
    ophthalmology, okayama university, Okayama city, Japan
  • Shinichiro Doi
    ophthalmology, okayama university, Okayama city, Japan
  • Masayuki Hirano
    ophthalmology, okayama university, Okayama city, Japan
  • Atsushi Fujiwara
    ophthalmology, okayama university, Okayama city, Japan
  • Mika Hosogi
    ophthalmology, okayama university, Okayama city, Japan
  • Fumio Shiraga
    ophthalmology, okayama university, Okayama city, Japan
  • Footnotes
    Commercial Relationships Mio Hosokawa, None; Yuki Morizane, None; Shuhei Kimura, None; Yusuke Shiode, None; Shinichiro Doi, None; Masayuki Hirano, None; Atsushi Fujiwara, None; Mika Hosogi, None; Fumio Shiraga, Alcon Japan (C), Alcon Japan (F), AMO Japan (F), Byer (C), Chuo Sangio Co. (F), Novartis Pharma (C), Novartis Pharma (F), Pfizer (F), Santen Pharmaceutical (C), Santen Pharmaceutical (F), Senju Pharmaceutical (F), Topcon Co. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4599. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mio Hosokawa, Yuki Morizane, Shuhei Kimura, Yusuke Shiode, Shinichiro Doi, Masayuki Hirano, Atsushi Fujiwara, Mika Hosogi, Fumio Shiraga; One-year results of intravitreal aflibercept injections for neovascular age-related macular degeneration using a treat and extend regimen. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4599.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the therapeutic effect of intravitreal aflibercept injections for neovascular age-related macular degeneration (nAMD) using a treat and extend regimen.

Methods: Thirty-one eyes of 31 nAMD patients, with a mean age of 73.5 (range, 55-88), were treated with 2 mg aflibercept injection monthly for at least 3 months. Monthly injections continued until no retinal exudative changes (i.e. new subretinal hemorrhage and subretinal and/or intraretinal fluid) were observed by optical coherence tomography. When no retinal exudative changes were seen, the interval to the next injection was extended by 2 weeks, up to a maximum of 12 weeks. If signs of exudation recurred, this interval was shortened by 2 weeks. The main outcome measures were 1) changes in best corrected visual acuity (BCVA), central retinal thickness (CRT), and retinal exudation, 2) annual number of injections and 3) the final interval between injections.

Results: The mean BCVA (logarithm of the minimal angle of resolution, log MAR) improved significantly from 0.37 ± 0.36 at baseline to 0.20 ± 0.27 at 1 year (p = 0.0002, paired t-test). BCVAs improved by more than 0.3 logMAR units in 7 eyes (22.6%) and were unchanged in 23 eyes (74.2%). The mean CRT decreased significantly from 329.2 ± 116.8 μm at baseline to 197.6 ± 54.4 μm at 1 year, (p < 0.0001, paired t - test). Retinal exudative changes had resolved completely in 26 eyes (83.9%) at 1 year. The mean number of injections was 8.2 ± 1.7 in a year. The mean interval between injections at 1 year was 9.3 ± 3.4 weeks.

Conclusions: The use of a treat and extend regimen for intravitreal aflibercept injections in nAMD was effective in improving BCVA, CRT, and retinal exudation at 1 year. The mean number of injections and the mean interval between them was very variable between cases.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×